You can also read the IBTA e-News August 2020 edition in full online here.
Some of the highlights from this month's round-up:
- Advancements in radiotherapy and drug treatments between 2007 and 2016 have led to real world improvements in survival for patients with brain metastases that have spread from melanoma skin cancer, according to research published in JAMA Network Open.
- Published in Nature Medicine, a pilot double-blind phase 3 clinical trial of 24 children with brain tumours who had received radiotherapy has found that treatment with metformin, a commonly used drug for type 2 diabetes, led to better improvements in cognitive function and signs of accelerated recovery of radiotherapy-induced brain damage, when compared to placebo.
- A study published in Clinical Cancer Research has analysed the results of three consecutive trials of dendritic cell (DC) vaccine therapy in glioblastoma and found that nearly a third of newly diagnosed glioblastoma patients treated became long-term survivors.
- A study in Nature Communications has identified a genetic mutation affecting the MGMT gene that can help explain how glioma tumours can develop a resistance to temozolomide chemotherapy. The research team used next generation gene sequencing technologies to uncover that mutations involving the fusion of MGMT with other genes can result in a dramatic increase in MGMT activity, allowing glioma cells to efficiently repair temozolomide damage and so grow despite treatment.
- More than 200 genes with both new and previously known roles in glioblastoma offer promising new drug targets, according to research published in Genome Biology.
- Drugs that block male sex hormones (anti-androgens) that are known to benefit prostate cancer patients undergoing radiotherapy may improve the outcome of a subset of glioblastoma patients, according to a study published in Molecular Cancer Therapeutics.
- Monteris Medical has announced the publication of a research paper, published in Neuro-Oncology Advances, supporting the use of laser interstitial thermal therapy (LITT) as a potential future surgical treatment for brain tumours.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to approximately 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.